CytoDyn (OTCMKTS:CYDY) Trading 4.4% Higher - Here's Why

Key Points

• CytoDyn Inc. experienced a significant increase in its stock price, rising 4.4% to $0.29 during mid-day trading.
• The company has a market capitalization of $360.16 million and a price-to-earnings ratio of 28.75.
• CytoDyn is involved in developing treatments for various conditions including COVID-19 and HIV through its monoclonal antibody, leronlimab.

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shot up 4.4% during trading on Monday . The stock traded as high as $0.30 and last traded at $0.29. 2,058,801 shares were traded during trading, an increase of 36% from the average session volume of 1,511,574 shares. The stock had previously closed at $0.28.

CytoDyn Price Performance

The firm has a 50-day moving average of $0.29 and a 200 day moving average of $0.28. The stock has a market capitalization of $372.45 million, a price-to-earnings ratio of 29.73 and a beta of 1.23.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last released its quarterly earnings data on Friday, July 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.